S*BIO takes $26M for cancer therapeutics

Pharmaceutical company S*BIO announced today that it raised $26 million in second-round funding to help push two new cancer treatment candidates through a second phase of clinical trials. Aravis Venture Associates and Bio*One Capital led the round, which also included Lacuna Apo BioTech and Zurcher Kantonalbank.

The Singapore-based company, which also has offices in Redwood City, Calif., has raised a total of $100 million since its inception in 2000. It received seed funding from Singapore Economic Development Board Investments and Chiron, reports VentureWire.

It will use its new funds to move its lead drugs from first to second-phase clinical trials. Both are cancer fighting compounds capable of targeting very specific disease-causing agents.

Next Story: Roundup: Web data offers election insight, banks gets big bonuses and more
Previous Story: Economic indicators jump — but start-up headache still setting in